Furthermore, Chen Y et al. recently showed that GLP-1 RAs improved time spent in range by T2D patients after 3–6 months of therapy versus OADs, with better results with once-weekly GLP-1 RAs versus once-daily GLP-1 RAs [37]. Here, GLP1R is linked to type 2 diabetes mellitus.